Aurobindo Pharma Subsidiary Expands MSD CMO Agreement

Aurobindo Pharma subsidiary TheraNym Biologics executed an additional product schedule with Merck Sharp & Dohme to expand their existing CMO relationship.
TheraNym will invest USD 150-175 million to build a new 60,000-liter mammalian drug substance manufacturing facility as a greenfield project.
This agreement expands the contract manufacturing operations for biologicals initiated in May 2024, with both domestic and international scope.
The disclosure was made pursuant to Regulation 30 of SEBI Listing Regulations on April 15, 2026.